REVERT – Improving care for patients with normal pressure hydrocephalus

In October 2021 the European Regional Development Fund (ERDF) via the Interreg France (Channel) England Programme awarded €2.4m to the University of Cambridge for REVERT – a project aiming to address the unmet need arising from an important health challenge: dementia.

Most forms of dementia are incurable, and its prevalence increases with age. Normal pressure hydrocephalus (NPH) can cause dementia and is potentially reversible. However, it is often mistaken for other incurable forms of dementia such as Alzheimer’s disease. The aim of REVERT is to implement innovative medical tools developed by individual partners to diagnose NPH patients quickly and accurately as part of an integrated care pathway.

A number of the project partners are regular collaborators with Orion Medtech, including its parent organisation, Obex technologies. REVERT involves cross-border collaboration between hospitals, healthcare academia and industry. It is led by the University of Cambridge in partnership with the University of Picardie Jules Verne and the University of Artois; the university hospitals of Cambridge, Amiens, Brest and Caen; and Obex Technologies, which will leverage the Orion platform to produce an integrated NPH management portal for clinicians.

REVERT was launched in October 2020 and will continue until June 2023. It has a budget of €3.5m of which €2.4m is being funded by the European Regional Development Fund (ERDF) via the Interreg France (Channel) England Programme.

Image credit: Ève Barlier